Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…09/11/2026

Stock CVS Health Corp. CVS

CVS Health Corp. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 13.39%

Price change 2019 → 2020: -8.06%

Price change 2020 → 2021: 51.04%

Price change 2021 → 2022: -9.66%

Price change 2022 → 2023: -15.27%

Price change 2023 → 2024: -43.15%

Price change 2024 → 2025: 76.79%

Price change 2025 → 2026: 11.37%

Price change 2026 (year to date): 10.30%

Financial growth

Revenue CAGR (8 years): 10.92%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 1.24

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 11.27

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 20.09% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
CVS Health Corporation11.51.24+10.0 %🔒
Sanofi9.40.28+2.5 %–
GSK plc10.71.08+0.9 %–
EssilorLuxottica S.A.34.10.37+14.2 %–
Moderna, Inc.–0.22+37.8 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

Key reported figures

Revenue, net income and net margin reported by CVS Health Corp. over the latest fiscal years.

Revenue
402 bn USD
fiscal year 2025
Net income
1.8 bn USD
fiscal year 2025
Net margin
0.4 %
fiscal year 2025
Average annual growth
+8.4 %
Revenue growth over 5 years
Average annual growth
+10.1 %
Revenue growth over 10 years
Market cap
107 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020269 bn7.2 bn2.7 %n/a
2021292 bn8.0 bn2.7 %+8.7 %
2022322 bn4.3 bn1.3 %+10.4 %
2023358 bn8.3 bn2.3 %+10.9 %
2024373 bn4.6 bn1.2 %+4.2 %
2025402 bn1.8 bn0.4 %+7.8 %

Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by CVS Health Corp. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
2.48
gray zone (1.81 to 2.99)
Piotroski Score
8 / 9
7 to 9: solid accounts
Net Debt / EBITDA
3.23 x
high debt
Fiscal year20212022202320242025
Cash and investments12.5 bn15.7 bn11.5 bn11.0 bn10.7 bn
Total Debt76.0 bn70.7 bn79.4 bn82.9 bn93.6 bn
Net Debt66.6 bn57.8 bn71.2 bn74.3 bn85.1 bn
Equity75.1 bn71.5 bn76.5 bn75.6 bn75.2 bn
Total assets233 bn228 bn250 bn253 bn261 bn
Operating cash flow18.3 bn16.2 bn13.4 bn9.1 bn10.6 bn
Investments (capex)2.5 bn2.7 bn3.0 bn2.8 bn2.8 bn
Free cash-flow15.7 bn13.4 bn10.4 bn6.3 bn7.8 bn
Share buybacks03.5 bn2.0 bn3.0 bn0
Dividends paid2.6 bn2.9 bn3.1 bn3.4 bn3.4 bn

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)9.68 x
Price / book value1.34 x
Return on Equity (ROE)14.1 %
Return on Invested Capital (ROIC)8.1 %
Net margin2.6 %
Debt / equity0.94 x
Current ratio0.85 x
Interest coverage4.91 x
Free cash-flow yield14.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.

+

Valuation and competitors

CVS Health Corp. compared with its sector on the same exchange and with its main competitors.

Company P/E
10.7
60.0 % below the sector
Sector median P/E
26.8
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
CVS Health Corp.115 bn11.50.4 %
UnitedHealth Group Incorporated UNH365 bn21.82.7 %
Cigna Corporation CI78.8 bn9.72.2 %
Elevance Health Inc. ELV91.1 bn14.32.8 %
Humana Inc. HUM49.8 bn26.10.9 %
Centene Corporation CNC33.9 bn27.2-3.4 %
Molina Healthcare, Inc. MOH10.7 bn29.61.0 %
Oscar Health, Inc. OSCR7.9 bn21.7-3.8 %
Alignment Healthcare, Inc. ALHC1.5 bn38.3-0.0 %
Sector median (NYSE)26.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering CVS Health Corp. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
41 analysts
Average price target
111.25 USD
from 92.00 USD to 123.00 USD, 40 targets over 12 months
Gap with the share price
+23.3 %
price 90.25 USD on 30/10/2026

Breakdown of ratings

strong buy 2buy 33hold 6sell 0strong sell 0

Average target over the last 3 months: 113.44 USD (9 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
2026417 bn10.3 bn8.05 (7.97 / 8.18)11.217
2027430 bn11.0 bn8.53 (8.45 / 8.94)10.618
2028449 bn12.4 bn9.70 (8.93 / 10.87)9.313

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
12/10/2026Leerink PartnersOutperformOutperform
03/09/2026UBSBuyBuy
19/08/2026Argus ResearchBuyBuy
12/08/2026JP MorganOverweightOverweight
06/08/2026Evercore ISI GroupOutperformOutperform

Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

CVS Health Corp.: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
0.665 USD
ex-dividend on 22/10/2026
Last 12 months
2.66 USD
number of payments: 4
Yield
3.4 %
on the last known price
Years of increases
0
consecutive
Years of payments
41
uninterrupted
00.671.332.002.662007 : 0.229 USD2008 : 0.258 USD20082009 : 0.305 USD2010 : 0.350 USD20102011 : 0.500 USD2012 : 0.650 USD20122013 : 0.900 USD2014 : 1.10 USD20142015 : 1.40 USD2016 : 1.70 USD20162017 : 2.00 USD2018 : 2.00 USD20182019 : 2.00 USD2020 : 2.00 USD20202021 : 2.00 USD2022 : 2.20 USD20222023 : 2.42 USD2024 : 2.66 USD20242025 : 2.66 USD2026 : 2.66 USD2026

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
22/10/20260.665 USD02/11/2026
23/07/20260.665 USD03/08/2026
23/04/20260.665 USD04/05/2026
22/01/20260.665 USD02/02/2026
23/10/20250.665 USD03/11/2025
22/07/20250.665 USD01/08/2025
22/04/20250.665 USD01/05/2025
23/01/20250.665 USD03/02/2025

Earnings releases

DatePublished EPSExpected EPSSurprise
05/08/20262.581.85+39.5 %
06/05/20262.572.18+17.9 %
10/02/20261.091.00+9.0 %
29/10/20251.601.37+16.8 %
31/07/20251.811.46+24.0 %
01/05/20252.251.70+32.4 %

Stock splits

DateOperation
07/06/2005split: 2 shares for 1
16/06/1998split: 2 shares for 1
15/03/1989split: 2 shares for 1
03/05/1983split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in CVS Health Corp.

Free float
99.8 %
share of freely traded shares
Institutions
90.3 %
2,173 declared holders, 2026Q2
Large funds tracked
38
hold the stock as of 2026Q2
Executives (insiders)
1 / 0
1 purchases, 0 sales in 130 days
US elected officials
16
7 purchases, 9 sales in 12 months

Indices: S&P 500 (since 04/03/1957).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
BlackRock123 m12.7 bn0.2 %-2.1 %2026Q2
State Street121 m12.5 bn0.2 %+103.2 %2026Q2
Vanguard Group121 m9.6 bn0.1 %+1.5 %2025Q4
Capital World Investors75.0 m7.8 bn0.9 %-3.0 %2026Q2
Dodge & Cox50.0 m5.2 bn2.7 %-3.4 %2026Q2
Wellington Management33.8 m3.5 bn0.6 %+49.8 %2026Q2
Geode Capital Management29.9 m3.1 bn0.2 %+1.5 %2026Q2
Fidelity28.9 m3.0 bn0.1 %-7.3 %2026Q2

Latest insider transactions

DatePersonSideAmount
06/11/2026Shah Prem Spurchase2.0 m USD

Elected officials' disclosures

DateOfficialSideAmount
04/09/2026Ro Khannasale$15,001 - $50,000
26/08/2024Thomas Hawley Tubervillesale$1,001 - $15,000
27/03/2026Alan Armstrongpurchase$1,001 - $15,000
02/06/2026Ro Khannapurchase$1,001 - $15,000
01/05/2026Ro Khannapurchase$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 20/11/1996
ISIN code
US1266501006
Workforce
219,000
full-time employees
Chief executive
J. David Joyner CEBS

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about CVS Health Corp.

What is the CVS Health Corp. share price?

Latest recorded price: 83.85 USD on 06/11/2026, for a market cap of 107 bn USD.

What is the revenue of CVS Health Corp.?

402 bn USD for fiscal year 2025, with net income of 1.8 bn USD (net margin 0.4 %).

Does CVS Health Corp. pay a dividend?

Yes. Latest dividend: 0.665 USD per share, ex-dividend on 22/10/2026. Over 12 months: 2.66 USD. Yield on the latest known price: 3.4 %.

What do analysts say about CVS Health Corp.?

Out of 41 analysts: 35 buy or strong buy, 6 hold, 0 sell or strong sell. Average price target: 111.25 USD, i.e. +23.3 % from the share price.

What is the P/E ratio of CVS Health Corp.?

Trailing 12-month P/E of 10.7, against 26.8 for the sector median on the same exchange (10-year median: 22.3).

Is CVS Health Corp. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US1266501006).

How many employees does CVS Health Corp. have?

219,000 full-time employees according to the latest published profile.

Who runs CVS Health Corp.?

J. David Joyner CEBS is the company's chief executive.

Which large funds own CVS Health Corp.?

As of 2026Q2, among the large funds tracked: BlackRock, State Street, Vanguard Group, Capital World Investors, Dodge & Cox.

07

Similar stocks